Home>News

JW Therapeutics opens R&D center in Zhangjiang

chinadaily.com.cn Updated:2018-12-19

图片11.png

Leading cell therapy company JW Therapeutics announces the opening of its R&D center in Zhangjiang Science City, Shanghai's Pudong New Area, Dec 12. [Photo/WeChat account: zjpark]

Leading cell therapy company JW Therapeutics announced on Dec 12 the opening of its research and development (R&D) center in Zhangjiang Science City, in Shanghai's Pudong New Area.

Covering an area of 2,500 square meters, the center will be committed to solving the problems of cellular immunotherapy in basic R&D, manufacturing techniques and quality management.

It will also focus its research on high-incidence diseases in China, and will seek partners worldwide to bring in and localize cutting-edge products and technology to benefit Chinese patients.

At the announcement, Li Yiping, co-founder and CEO of JW Therapeutics, noted the importance of the center to the company and said it will continue to pursue innovation for the further development of cellular immunotherapy in China.

JW Therapeutics is a joint effort of Juno Therapeutics, a leading global cell-based cancer immunotherapy company, and WuXi App Tec, a leading pharmaceutical, biotechnology and medical devices R&D platform company with global operations.

The joint company is working on building a cell therapy technical platform integrating R&D, production and marketing. It has taken the lead in China in clinical research of chimeric antigen receptor T-cell immunotherapy (CAR-T).

1 2 >